In silico structure-based design of a novel class of potent and selective small peptide inhibitor of Mycobacterium tuberculosis Dihydrofolate reductase, a potential target for anti-TB drug discovery.
Kumar, Manoj
In silico structure-based design of a novel class of potent and selective small peptide inhibitor of Mycobacterium tuberculosis Dihydrofolate reductase, a potential target for anti-TB drug discovery. [electronic resource] - Molecular diversity Aug 2010 - 595-604 p. digital
Publication Type: Journal Article
1573-501X
10.1007/s11030-009-9172-6 doi
Amino Acid Sequence
Antitubercular Agents--chemistry
Binding Sites
Computational Biology--methods
Crystallography, X-Ray
Drug Design
Folic Acid Antagonists--chemistry
Humans
Hydrogen Bonding--drug effects
Ligands
Methotrexate--chemistry
Microbial Sensitivity Tests
Molecular Dynamics Simulation
Molecular Sequence Data
Mycobacterium tuberculosis--drug effects
Ornithine--analogs & derivatives
Peptides--chemistry
Pterins--chemistry
Reproducibility of Results
Substrate Specificity--drug effects
Tetrahydrofolate Dehydrogenase--metabolism
Triazines--chemistry
Tuberculosis--drug therapy
In silico structure-based design of a novel class of potent and selective small peptide inhibitor of Mycobacterium tuberculosis Dihydrofolate reductase, a potential target for anti-TB drug discovery. [electronic resource] - Molecular diversity Aug 2010 - 595-604 p. digital
Publication Type: Journal Article
1573-501X
10.1007/s11030-009-9172-6 doi
Amino Acid Sequence
Antitubercular Agents--chemistry
Binding Sites
Computational Biology--methods
Crystallography, X-Ray
Drug Design
Folic Acid Antagonists--chemistry
Humans
Hydrogen Bonding--drug effects
Ligands
Methotrexate--chemistry
Microbial Sensitivity Tests
Molecular Dynamics Simulation
Molecular Sequence Data
Mycobacterium tuberculosis--drug effects
Ornithine--analogs & derivatives
Peptides--chemistry
Pterins--chemistry
Reproducibility of Results
Substrate Specificity--drug effects
Tetrahydrofolate Dehydrogenase--metabolism
Triazines--chemistry
Tuberculosis--drug therapy